Search results: (10000)
News Changes in Intestinal Microflora Correlate with Disease Activity in Patients with Lupus Erythematosus
The role of intestinal microflora in the pathogenesis of autoimmune diseases, including lupus erythematosus, has been discussed for a long time. An American study discovered a specific bacterium whose proliferation in the intestine correlates not only with the occurrence of the disease but also with its activity.
News MS in Children – An Overlooked Sister of Adult Diseases?
Multiple sclerosis is not just an adult disease. How common is it in children and how have current therapeutic possibilities advanced for this population both in our country and around the world?
News Safety and Tolerability of Bilastine in the Treatment of Chronic Urticaria in Children
Chronic urticaria is less common in pediatric patients compared to the acute form, but it always requires therapy due to bothersome chronic symptoms that reduce quality of life and disrupt daily activities of affected children. According to recent guidelines, the first-line treatment is non-sedating second-generation antihistamines, among which bilastine is included.
News Fatigue and Quality of Life in Patients with Primary Biliary Cholangitis
Fatigue is the most common symptom of primary biliary cholangitis (PBC). Its occurrence significantly impacts the health-related quality of life of patients.
News AAD 2023: Efficacy of Bimekizumab in the Treatment of Hidradenitis Suppurativa
At the latest annual congress of the American Academy of Dermatology (AAD), held March 17-22, 2023 in New Orleans, the results of the phase III BE HEARD I and II studies were presented among late-breaking presentations. The studies demonstrate the safety and high efficacy of bimekizumab in the treatment of adults with moderate to severe hidradenitis suppurativa (HS).
News Expert Consensus on the Use of Bimekizumab in the Treatment of Plaque Psoriasis and Psoriatic Arthritis
The expert consensus published in February 2024 offers guidance on the use of bimekizumab in the treatment of patients with moderate to severe plaque psoriasis and psoriatic arthritis. It is based on a literature review and an assessment of data from 19 relevant studies. A panel of 9 American dermatologists specializing in psoriasis treatment created and adopted 14 consensus statements and recommendations, 12 of which have a strength of “A”.
News Combined Hormonal Contraception in the Treatment of Dysmenorrhea
Dysmenorrhea troubles many women of reproductive age and can deteriorate their quality of life, making it important for doctors to offer suitable therapy. We summarize the findings of research on the use of hormonal contraception containing drospirenone (DRSP) and ethinylestradiol (EE) in the treatment of dysmenorrhea.
News Comparison of the Effect of Sonic and Manual Toothbrushes on Dental Plaque and Gingivitis Control
A clinical study on healthy volunteers with mild to moderate gingivitis compared the effectiveness of sonic and manual toothbrushes in terms of dental plaque and gingivitis occurrence. The results of the study showed that the sonic toothbrush outperformed the manual one in all observed parameters.
News FEIBA in Real Clinical Practice – Fresh Data from the Observational Study FEIBA GO
FEIBA GO (Global Outcome) was a prospective observational study evaluating the long-term administration of FEIBA, its safety, efficacy, and quality of life for patients with hemophilia A or B and high-titer inhibitors (high responders), who were receiving aPCC in routine clinical practice. The study, whose results were recently published, was conducted at 25 centers in 11 countries.
News Teriflunomide vs. Dimethyl Fumarate: Does Their Classification into Different Treatment Lines Have Merit?
Teriflunomide is one of the first-choice medications in the treatment of multiple sclerosis (MS) patients, not only in the Czech Republic. Conversely, the use of dimethyl fumarate is more limited here compared to other countries. Did the data from real-world clinical practice published this year actually demonstrate differences in the efficacy of both medications, and thus justify their classification?
News Use of Medical Cannabis in Patients with Fibromyalgia to Relieve Pain and Depression
Medical cannabis is prescribed to patients with chronic pain resistant to conventional treatments. The efficacy of tetrahydrocannabinol (THC) therapy in patients with fibromyalgia syndrome (FMS) was recently evaluated in a German study.
News Long-term effect of the triple combination of perindopril, indapamide, and amlodipine on left ventricular hypertrophy in hypertension
A recent open-label interventional study aimed to describe the long-term effect of a fixed triple combination of perindopril, indapamide, and amlodipine compared to a free combination of a RAAS inhibitor, diuretic, and calcium channel blocker on the reduction of left ventricular hypertrophy (LVH) in hypertensive outpatients.
News Bilastine and its role in the treatment of allergic rhinoconjunctivitis and urticaria in children
The prevalence of allergic rhinitis (AR) in the pediatric population is estimated worldwide at 10-20%. The efficacy and safety of bilastine (a second-generation antihistamine) in adult patients and adolescents have already been proven in clinical studies. Below we summarize experiences with its use in children under 12 years of age.
News Impact of Azacitidine Maintenance Therapy on Survival of Patients with AML in Remission Depending on Initial Chemotherapy
The QUAZAR AML-001 study showed that oral azacitidine maintenance therapy significantly prolongs relapse-free survival (RFS) and overall survival (OS) in patients with acute myeloid leukemia (AML) in first remission after intensive chemotherapy (including induction ± consolidation therapy), who are not candidates for hematopoietic stem cell transplantation (HSCT), compared to placebo. In October 2023, results of a subgroup analysis of patients stratified according to the use/non-use of consolidation chemotherapy and the number of consolidation chemotherapy cycles administered before entering the study were published.
News Venous Insufficiency of the Lower Extremities – A Diverse Range of Risks, Manifestations, and Complications
Although initially often asymptomatic, chronic venous insufficiency includes a variety of symptoms. Some of its manifestations can be irreversible, increasing the socio-economic burden that this disease, especially in its advanced stages, represents. German authors have summarized the latest findings on the epidemiology, risks, pathogenesis, manifestations, and complications of CVI in their review.
News Older patients with CLL and comorbidities: an option for treatment with immunotherapy without chemotherapy?
Is it time to treat chronic lymphocytic leukemia (CLL) without chemotherapy? The authors of a recently published article in the Expert Review of Hematology journal attempted to answer this question.
News What is the Impact of Bisoprolol on Plasma Concentrations of Dabigatran
Many patients on anticoagulant therapy with dabigatran also use the beta-blocker bisoprolol. The Slovak prospective observational study was based on the assumption that bisoprolol, as a significant inhibitor of P-glycoprotein, may interact with dabigatran and focused on examining the effect of this beta-blocker on plasma concentrations of dabigatran.
News The Link Between Various Sleep Disorders and the Onset of Depression: What Findings Did the Population Study in Denmark Bring?
A Danish population study published in June 2019 examined the link between different types of sleep disorders and the risk of developing depression. Which disorders confirmed this link after evaluating data from tens of thousands of patients?
News Post hoc Analysis of the FRAME Study – Romosozumab in the Treatment of Osteoporosis in the European Population
An interesting finding from the FRAME study, which evaluated the treatment of postmenopausal women with osteoporosis using romosozumab, was the significant differences in fracture incidence among patients from various geographic regions. The following post hoc analysis specifically focused on data from European women.
News Domestic application of biological asthma treatment improves quality of life and reduces doctor visits
The benefits of the possibility of home application of omalizumab, a monoclonal antibody indicated for patients with severe allergic asthma, are summarized by Dr. Jakub Novosad, Ph.D., from the Institute of Clinical Immunology and Allergology, Charles University Medical Faculty and University Hospital Hradec Králové.
News Three tests to confirm the diagnosis of acquired hemophilia – infographic
Acquired hemophilia (AHA) typically manifests with spontaneous bleeding in patients with no prior personal history of significant bleeding.1–4 The cause of the bleeding is a significant decrease in FVIII activity induced by autoantibodies against coagulation factor VIII.5 In polymorbid patients, established antithrombotic therapy at the time of AHA diagnosis may also contribute to the bleeding.4
News Eletriptan and Its Role in Acute Migraine Therapy
In the acute treatment of moderate to severe migraine attacks, medications from the triptan group are primarily used. The following article summarizes important findings about eletriptan and its key results in clinical studies.
News Bimekizumab – Higher Chance of Complete Skin Healing in Moderate to Severe Psoriasis?
In August 2021, the European Medicines Agency (EMA) approved bimekizumab (Bimzelx LP) as the first psoriasis treatment that selectively and directly inhibits interleukins IL-17A and IL-17F. It is intended for the treatment of moderate to severe plaque psoriasis in adults for whom systemic treatment is appropriate. The approval is based on three Phase III clinical studies in which bimekizumab demonstrated a very high rate of skin healing compared to placebo and active treatments like ustekinumab and adalimumab, as well as good tolerability.
News Pertuzumab significantly extends the life of patients with metastatic breast cancer
The final results of the CLEOPATRA clinical trial show that patients with HER2-positive metastatic breast cancer achieve 8-year overall survival of 37% with the targeted treatment combination of pertuzumab + trastuzumab + docetaxel.